" class="no-js "lang="en-US"> Jay Mei - Medtech Alert
Wednesday, March 22, 2023
Jay Mei

Jay Mei

About Jay Mei

Related Story

Antengene Announces Research Collaboration with Celularity to Evaluate the Potential Therapeutic Synergy of Combining Antengene's Best-in-Class Bispecific Antibody with Celularity's Natural Killer Cell Platform

July 21 2022

Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, […]

Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma

June 27 2022

Antengene Corporation Limited (“Antengene“ SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, […]

Antengene Announces XPOVIO ® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications

March 2 2022

Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, […]

Antengene and XtalPi Announce AI-Driven R&D Collaboration

December 16 2021

Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, […]

Antengene Enters into a Research Collaboration & License Option Agreement with LegoChem Biosciences for New Antibody-Drug Conjugate Candidates

October 21 2021

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing […]